Comparison of Anyu Peibo With Placebo in Treatment of MDD

NCT ID: NCT02380066

Last Updated: 2020-01-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 120 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-03-31
• Study Completion Date: 2017-01-31

Brief Summary

The purpose of this study is to determine whether Anyu Peibo Capsule in different doses are effective in the treatment of Depression.

And to explore the preliminary information of safety and efficacy of Anyu Peibo Capsule in the Chinese Patients with Depression.

Conditions

Major Depressive Disorder (MDD)

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Anyu Peibo 0.4g per day

Anyu Peibo Capsule, oral, 0.2g twice per day

Group Type: EXPERIMENTAL

Anyu Peibo

Intervention Type: DRUG

Placebo

Anyu Peibo 0.8g per day

Anyu Peibo Capsule, oral, 0.4g twice per day

Group Type: EXPERIMENTAL

Anyu Peibo

Intervention Type: DRUG

Placebo

Anyu Peibo 1.2g per day

Anyu Peibo Capsule, oral, 0.6g twice per day

Group Type: EXPERIMENTAL

Anyu Peibo

Intervention Type: DRUG

Placebo

Anyu Peibo 1.6g per day

Anyu Peibo Capsule, oral, 0.8g twice per day

Group Type: EXPERIMENTAL

Anyu Peibo

Intervention Type: DRUG

Placebo

Placebo

Placebo,oral, twice per day

Group Type: PLACEBO_COMPARATOR

Anyu Peibo

Intervention Type: DRUG

Placebo

Interventions

Anyu Peibo

Placebo

Intervention Type: DRUG

Other Intervention Names

Placebo

Eligibility Criteria

Inclusion Criteria

• Adult with primary diagnosis of major depressive disorder(MDD) based on the criteria of DSM-IV-TR, single episode or recurrent episode, not accompanied with psychotic symptoms. Coding of diagnosis included: 296.21 MDD single episode, mild 296.22 MDD single episode, moderate 296.31 MDD recurrent episode, mild 296.32 MDD recurrent episode, moderate
• The total score of HAMD-17 is ≥18 and ≤24 in both screening visit and baseline visit.
• The subject understands and consents to takes part in this clinical trials. The subjects should sign informed consent.

Exclusion Criteria

• The subject has a significant risk of suicide according to the investigator's opinion or has a score ≥3 on item 3(suicide assessment) of the HAMD or has made a suicide attempt.
• The subject has a current DSM-Ⅳ-TR axisⅠpsychiatric diagnosis other than depression.
• When the HAMD17 score of baseline visit compares with the screening visit, the decreasing rate is ≥25%.
• Any unstable cardiovascular, hepatic, renal, endocrine(thyroid gland dysfunction), blood,or other medical disease.
• Had a history of seizure disorder,except infantile febrile convulsion.
• The subject has accepted psychosurgery or electroconvulsive therapy within 3months.
• With psychotic symptoms.
• The subject has a history of mania episode, including manic, mixed or rapid cycle attack.
• The subject has a current diagnosis or history of depression due to any other psychotic disorder or a general medical condition.
• The subject with refractory depressive disorder,i.e.the patients who used at least two different mechanisms antidepressants with adequate dosage and duration treatment still had no respond.
• Clinically significant electrocardiographic(ECG) abnormalities or abnormal laboratory values(eg. Hepatic function above 1.5 times of clinical toplimit, renal function or thyroid gland function index above toplimit, routine blood, fasting blood glucose value above or below 1.1 times of the upper limit of normal or in 1.1 times with the clinical significance of abnormality).
• The subject has a diagnosis of alcohol or other substance abuse or dependence at least 1 years prior to the baseline visit.
• Known hypersensitivity to Big Leaf Ju, or at least to two kinds of drugs, or serious allergic physique.
• Women who were pregnant, breast-feeding, or planning to become pregnant during study. Men who have request to fertility during study period. The subject could not take safe and effective birth control measures.
• The subject could not take medication according to the doctor's advice. i.e. the compliance of the subject is poor.
• The subject uses antidepressant drug normally before 2 weeks of screening, and stops using psychotropic drug less than 7 half-life period (monoamine oxidase inhibitor more than 2 weeks, fluoxetine more than 1 month).
• The subject has participated in a drug clinical trial within 1 month before screening.
• The investigator think the subject is unsuitable to enrol in this clinical trial.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Su Zhou YiHua Biotechnology Co. LTD

UNKNOWN

Sponsor Role: collaborator

Shanghai Mental Health Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Huafang LI, MD PhD

Role: PRINCIPAL_INVESTIGATOR

Shanghai Mental Health Center

Locations

Anhui province hospital of TCM

Hefei, Anhui, China

Guang'anmen Hospital

Beijing, Beijing Municipality, China

Peking University Sixth Hospital

Beijing, Beijing Municipality, China

Guangzhou Huiai Hospital

Guangzhou, Guangdong, China

Jiangsu province hospital of TCM

Nanjing, Jiangsu, China

Wuxi Mental Health Center

Wuxi, Jiangsu, China

Countries

China

Other Identifiers

2012ZX09303-003

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

AYPB-MDD-Ⅱa-1401

Identifier Type: -

Identifier Source: org_study_id